Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 3, Issue 5, 2008, Pages 511-515

  Lilenbaum, Rogerio ^a,d   Raez, Luis ^b   Tseng, Jennifer ^c   Seigel, Leonard ^a   Davila, Enrique ^a  

^a Miami Beach FL   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c M D ANDERSON CANCER CENTER ORLANDO   (United States)

^d Mount Sinai Cancer Center   (United States)

Author keywords

Advanced non small cell lung cancer; Bevacizumab; Gemcitabine; Oxaliplatin

Indexed keywords

BEVACIZUMAB; GEMCITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; CANCER CONTROL; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; FEMALE; HUMAN; HYPERTENSION; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STROKE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE;

EID: 43049127188     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31816de28f     Document Type: Article

References (25)

1. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology Non-small cell lung cancer 1 2007 1 55 Available at: http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf Accessed July 31, 2007.
2. F Fossella JR Pereira J von Pawel Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group J Clin Oncol 21 2003 3016 3024
3. GV Scagliotti F De Marinis M Rinaldi Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer J Clin Oncol 20 2002 4285 4291
4. JH Schiller D Harrington CP Belani Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer N Engl J Med 346 2002 92 98
5. S Faivre E Raymond JM Woynarowski Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines Cancer Chemother Pharmacol 44 1999 117 123
6. P Bidoli N Zilembo D Cortinovis Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study Ann Oncol 18 2007 461 467
7. A Broad M Links MA Rosenthal Combination gemcitabine and oxaliplatin for advanced non small cell lung cancer (NSCLC): an Australian multicenter randomized phase II sequencing trial J Clin Oncol 23 16S Suppl 2005 681s (abstract 7244).
8. F Cappuzzo S Novello F De Marinis Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer Br J Cancer 93 2005 29 34
9. JL Misset P Vennin PH Chollet Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients Ann Oncol 12 2001 1411 1415
10. GV Scagliotti C Kortsik GG Dark Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial Clin Cancer Res 11 2 Pt 1 2005 690 696
11. A Sandler R Gray MC Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
12. S Shibata W Chow P Frankel A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression Cancer Chemother Pharmacol 59 2007 549 557
13. IE Smith ME O'Brien DC Talbot Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin J Clin Oncol 19 2001 1336 1343
14. MA Socinski MJ Schell A Peterman Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer J Clin Oncol 20 2002 1335 1343
15. C von Plessen B Bergman O Andresen Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer Br J Cancer 95 2006 966 973
16. H Ozer JO Armitage CL Bennett 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel J Clin Oncol 18 2000 3558 3585
17. P Therasse SG Arbuck EA Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
18. J Lawless Statistical Models and Methods for Lifetime Data 1982 John Wiley and Sons New York
19. DW Hosmer Jr S Lemeshow Applied Survival Analysis 1999 Wiley & Sons New York
20. DH Johnson L Fehrenbacher WF Novotny Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2004 2184 2191
21. C Manegold J von Pawel P Zatloukal Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 J Clin Oncol 25 18S Suppl 2007 Abstract LBA7514 and slides.
22. H Hurwitz L Fehrenbacher W Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
23. FF Kabbinavar J Schulz M McCleod Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial J Clin Oncol 23 2005 3697 3705
24. JC Yang L Haworth RM Sherry A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427 434
25. LE Raez ES Santos G Lopes Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC) Lung Cancer 53 2006 347 353